Drug Trial Radar · NCT06501534
A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
Last checked: Nov 20, 2026Latest source record: Mar 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Jul 10, 2024
Primary completion
Dec 13, 2024
Study completion Jan 9, 2025
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
IBI128 (Tigulixostat) is a novel non-purine selective inhibitor of xanthine oxidase (XO). The XO inhibitors lower uric acid concentrations in serum by inhibiting the production of uric acid. This ia a randomized, open label, multicenter, parallel-group, positive-controlled, dose finding, and Phase II study to assess efficacy and safety of IBI128 in chinese gout subjects.
Conditions
- Gout
- Hyperuricemia
Interventions
FebuxostatDrug
Tablets, Once a day (QD), Per oral
IBI128Drug
Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects in each treatment group with serum uric acid levels <360 μmol/L after continuous treatment for 16 weeksTime frame: Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Fudan University HuaShan Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.